Price$16.15-3.07 (-15.97%)
2026-03-052026-06-08
News · 26 weeks74-35%
2025-12-142026-06-07
Mix4990d
- Other24(49%)
- Insider13(27%)
- SEC Filings6(12%)
- Analyst4(8%)
- Earnings2(4%)
Latest news
25 items- PRCaris Life Sciences Announces Share Repurchase ProgramIRVING, Texas, June 8, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI) ("Caris" or the "Company"), a leading next-generation AI TechBio company and precision medicine pioneer, today announced that its Board of Directors has authorized a share repurchase program for up to $100 million of the Company's outstanding common stock. Under the repurchase program, the Company may repurchase shares from time to time through open market purchases, in privately negotiated transactions, or by other means, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934, as ame
- SECCaris Life Sciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Caris Life Sciences, Inc. (0002019410) (Filer)
- INSIDERDirector Poste George was granted 1,600 shares, increasing direct ownership by 10% to 17,729 units (SEC Form 4)4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
- INSIDERDirector Knowles Jonathan Kenneth Charles was granted 1,600 shares, increasing direct ownership by 0.52% to 308,979 units (SEC Form 4)4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
- ANALYSTWolfe Research resumed coverage on Caris Life SciencesWolfe Research resumed coverage of Caris Life Sciences with a rating of Peer Perform
- PRCaris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic TestingInaugural story spotlights a woman whose presumed stage 4 metastatic breast cancer diagnosis was corrected by Caris GPSai, an AI-powered tissue-of-origin model, revealing a highly treatable lymphomaIRVING, Texas, May 26, 2026 /PRNewswire/ -- Caris Life Sciences®, Inc. (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today launched "Behind the Diagnosis," a new campaign that spotlights patients whose care has been targeted and personalized by Caris' comprehensive molecular profiling and AI-powered precision medicine. The inaugural story features Erika Rios, who was diagnosed prior to Caris testing, with stage 4 metastatic triple-nega
- INSIDEROfficer Denton John Russel covered exercise/tax liability with 6,047 shares, decreasing direct ownership by 3% to 181,515 units (SEC Form 4)4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
- INSIDEROfficer Power Luke Thomas covered exercise/tax liability with 9,771 shares, decreasing direct ownership by 6% to 153,771 units (SEC Form 4)4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
- INSIDEROfficer Brille Brian J covered exercise/tax liability with 13,987 shares, decreasing direct ownership by 6% to 230,303 units (SEC Form 4)4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
- INSIDERPresident Spetzler David Baxley covered exercise/tax liability with 13,856 shares, decreasing direct ownership by 3% to 530,083 units (SEC Form 4)4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
- INSIDEROfficer Halbert David D covered exercise/tax liability with 40,712 shares, decreasing direct ownership by 2% to 2,574,533 units (SEC Form 4)4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
- PRCaris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer SeekThe Caris Lookback Program identified 13,293 patients potentially eligible for newly approved targeted therapies across 10 tumor types IRVING, Texas, May 15, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the publication of a Caris‑led study in The Oncologist demonstrating the ability of the Caris Lookback Program to proactively identify previously-profiled patients who become eligible for newly approved targeted therapies. Molecular profiling reports from most
- PRReal-Time Intoxication Detection Platforms Target Expanding Multibillion-Dollar Healthcare OpportunitiesAUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: For decades, reliably identifying drug and alcohol impairment has been a persistent problem across industries, from traffic enforcement and occupational safety to clinical medicine and public health. Conventional tools such as breathalyzers, blood draws and urine tests are hampered by their intrusiveness, slow turnaround times or inability to capture real-time impairment, especially when multiple substances are involved. As substance-use patterns shift and the broader societal costs of intoxication continue to mount, the pressure to develop faster, less invasive, and more scalable detection methods is intensifyi
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Caris Life Sciences Inc.SCHEDULE 13G/A - Caris Life Sciences, Inc. (0002019410) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Caris Life Sciences Inc.SCHEDULE 13G/A - Caris Life Sciences, Inc. (0002019410) (Subject)
- INSIDERDirector Vacirca Jeff L bought $501,426 worth of shares (31,050 units at $16.15), increasing direct ownership by 167% to 49,671 units (SEC Form 4)4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
- PRCaris Life Sciences Publishes Study Showing Whole Exome Measurement of Tumor Mutational Burden Results in Increased Overall Survival Compared to Estimates from Targeted Gene PanelsTargeted gene panels miscalculate tumor mutational burden in 10–15% of patients, directly resulting in incorrect pembrolizumab eligibility determinationIRVING, Texas, May 11, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has published a study in Cancer Immunology, Immunotherapy demonstrating that measuring tumor mutational burden (TMB) using ultra-deep Whole Exome Sequencing (WES) provides superior prediction of pembrolizumab immunotherapy benefit compared to estimates of TMB from targeted gene panels. TMB is a pan-tumor biomarker used to determine patients' eligibility for pembrolizumab.
- SECSEC Form 10-Q filed by Caris Life Sciences Inc.10-Q - Caris Life Sciences, Inc. (0002019410) (Filer)
- PRCaris Life Sciences Submits Application to New York State Department of Health for Caris Assure Blood‑Based Testing AuthorizationIRVING, Texas, May 8, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced that it has submitted an application to the New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program (CLEP), administered through the Wadsworth Center, seeking authorization to perform Caris Assure®, its blood‑based molecular profiling test, on specimens originating from New York State. Caris Assure is a blood‑based molecular profiling test designed to support comprehe
- SECCaris Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Caris Life Sciences, Inc. (0002019410) (Filer)
- PRCaris Life Sciences Reports First Quarter 2026 Financial ResultsRevenue growth of 79% driven by strong performance in molecular profiling servicesIRVING, Texas, May 7, 2026 /PRNewswire/ -- Caris Life Sciences, Inc. (NASDAQ:CAI), a leading, patient centric, next-generation AI TechBio company and precision medicine pioneer, today reported financial results for the quarter ended March 31, 2026. First Quarter 2026 Financial HighlightsReported total revenue of $216.2 million, an increase of 79% over the corresponding prior year period.Completed approximately 52,800 clinical therapy selection cases, an increase of approximately 15% over the corres
- PRCaris Life Sciences Launches Caris MI Clarity, the First and Only AI-Powered Test to Predict Both Early and Late Distant Recurrence Risk in Breast Cancer at the Time of DiagnosisCaris MI Clarity leverages AI to transform how recurrence risk is understood and applied in postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancerIRVING, Texas, May 5, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced the launch of Caris MI Clarity™, the first prognostic test designed to deliver insight into both early and late distant recurrence risk for postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer at the time of diagnosis. Results are typically provided to the ordering physician within
- PRCaris Life Sciences Receives MolDX Approval for Caris ChromoSeq, Advancing Access to Comprehensive Genomic Profiling for Myeloid MalignanciesIRVING, Texas, May 4, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient‑centric, next‑generation AI TechBio company and precision medicine pioneer, today announced that Caris ChromoSeq™ has received MolDX approval, a key milestone supporting broader clinical access to Caris' comprehensive whole genome tumor profiling assay for myeloid malignancies. The Molecular Diagnostic Services (MolDX) program, administered by Palmetto GBA on behalf of the Centers for Medicare & Medicaid Services (CMS), evaluates molecular diagnostic tests to determine whether they d
- PRCaris Life Sciences Publishes Study Validating Caris AI Insights for Temozolomide Benefit in Glioblastoma PatientsCaris AI Insights are proprietary and only available to Caris Life Sciences customersIRVING, Texas, April 29, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, announced the development and peer-reviewed validation of a new predictive signature to inform therapy selection in glioblastoma (GBM) patients. The study, published in Neuro-Oncology Advances, describes the development and evaluation of the model in a cohort of more than 5,800 GBM patients. The Caris AI Insights in Glioblastoma is featured on the Caris Molecular Tumor Board Report, an innovative profiling report that provides addition
- PRCaris Life Sciences to Present at the BofA Securities 2026 Health Care Conference and the Goldman Sachs 47th Annual Global Healthcare ConferenceIRVING, Texas, April 24, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company will present at the BofA Securities 2026 Health Care Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. The BofA Securities 2026 Health Care Conference will be held on May 12-14, 2026, in Las Vegas, Nevada. Caris will present on Tuesday, May 12, from 10:00 - 10:30 AM PT.The Goldman Sachs 47th Annual Global Healthcare Conference will be held on June 8
CAI FAQ
7 questionsWhat does Caris Life Sciences Inc. do?
CAI International, Inc. operates as a transportation finance company in the United States, Switzerland, France, Korea, Singapore, rest of Asia, rest of Europe, and internationally. The company leases, re-leases, and disposes equipment; and contracts for the repair, repositioning, and storage of equipment. It leases its container equipment to lessees under long-term, short-term, and finance leases. The company also sells containers; and manages equipment for to third-party investors, as well as sells used containers. As of December 31, 2020, it had a container fleet comprised 1,798,520 cost...Where does CAI stock trade?
Caris Life Sciences Inc. (CAI) is listed on NYSE.What sector and industry is CAI in?
Caris Life Sciences Inc. operates in the Health Care sector, Medical Specialities industry.When did Caris Life Sciences Inc. go public?
Caris Life Sciences Inc. (CAI) completed its IPO in 2025.What are analysts saying about CAI?
Caris Life Sciences Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Peer Perform on 2026-06-02. Recent price targets range from $2100.00 to $3100.00.What companies are similar to CAI?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), HUM (Humana Inc.). Compare CAI side-by-side with any of them on Quantisnow.How can I track CAI on Quantisnow?
Quantisnow aggregates Caris Life Sciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CAI to receive live email and push alerts on every new disclosure.